AbbVie Advances Real-world Study on OZURDEX for Diabetic Macular Edema in China

Abbvie ((ABBV)), Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study.

AbbVie is conducting a real-world observational study titled ‘A Two-year Non-interventional, Real-world, Observational Study to Assess Safety of OZURDEX® (Dexamethasone Intravitreal Implant) in Patients With Diabetic Macular Edema in China.’ The study aims to evaluate the long-term safety and effectiveness of the OZURDEX implant in adult patients with diabetic macular edema (DME) in China. This research is significant as it provides insights into the real-world application of OZURDEX, a treatment already approved for DME.

The intervention being tested is the OZURDEX (dexamethasone intravitreal implant), which is designed to release dexamethasone gradually to the retina, targeting diabetic macular edema. The purpose is to monitor its safety and effectiveness over an extended period in a real-world setting.

The study is observational with a case-only model and a prospective time perspective. It involves observing participants who are prescribed OZURDEX in routine clinical practice, with no additional interventions or burdens imposed on them. The primary purpose is to gather safety data over a 24-month period.

The study began on November 13, 2024, with a primary completion date yet to be determined. The last update was submitted on June 24, 2025. These dates are crucial for tracking the study’s progress and ensuring timely updates for stakeholders.

This update could influence AbbVie’s stock performance positively by reinforcing investor confidence in the company’s commitment to safety and efficacy in real-world settings. It also positions AbbVie competitively within the pharmaceutical industry, particularly in the ophthalmology sector.

The study is ongoing, and further details are available on the ClinicalTrials portal.